News

The first four fund investments have now been made. So far, BGF has invested in Fortino Capital II Growth, SmartFin Capital II, Sofindev V and Gilde Healthcare V. A new, fifth fund investment of EUR 20 million is announced in Forbion Growth Opportunities Fund I. Forbion is a specialist European fund manager with more than EUR 1 billion of assets under management in life sciences and biotechnology. The new fund, with an initial fund size of €185 million, focuses on growth opportunities with a focus on the later stage in life sciences and biotechnology. Forbion wants to approach the market through three strategies and focuses on growth capital, pre-IPO financing and the support of undervalued companies. The advisory committee includes Tim van Hauwermeiren (CEO Argenx), Onno van de Stolpe (CEO Galapagos) and Jan van de Winkel (CEO Genmab).

Ambition

"We are delighted with our entry into Forbion Growth Opportunities I. The participation reinforces our ambition to further support the Belgian biotech sector through funds with a proven Belgian activity and track record. In the past, Forbion has had important Belgian companies in its portfolio, including Argenx". said Mireille Kielemoes (BGF).